MTHFD2 and bladder transitional cell carcinoma: Collectively, different from previous studies that mainly focused on its roles in cancer cells, such as promoting cancer cell proliferation and participating in transcriptional regulation and metabolic reprogramming, regarding MTHFD2 as a novel promising target for cancer therapy (23, 24, 74), our study concentrated on its correlation with cancer immunity and revealed that MTHFD2 could be a robust biomarker for immunotherapy outcomes in BLCA.